Previous 10 | Next 10 |
The U.S. Food and Drug Administration (FDA) granted fast track designation to Biohaven ( NYSE: BHVN ) medicine taldefgrobep alfa to treat spinal muscular atrophy (SMA). SMA is an inherited motor neuron disorder characterized by loss of nerve cells leading to muscle weakness over time....
Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy PR Newswire - Taldefgrobep alfa, a myostatin-targeting biologic investigational agent, in Phase 3 development to increase muscle mass for Spinal Muscular Atrophy patients now grant...
Summary The S&P 500 is just too expensive at this level. It will be brought to heal by rising rates and lower earnings. A long-short strategy along with hedging the indexes and maintaining a cash management discipline creates the right configuration for trading success. ...
Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Higher interest rates created a difficult year for ...
Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire NEW HAVEN, Conn. , Jan. 6, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 4...
JP Morgan has started Biohaven ( NYSE: BHVN ) off with an overweight rating saying that lead candidate BHV-7000 holds promise in several neurological indications and its pipeline is encouraging. The firm has a $23 price target (~70% upside based on Monday's close). Shares are up...
Summary In today's article, we bring you the latest update in our recurring series based on analyzing 13F filings and the latest moves of some of the world's most renowned funds. Soros Fund Management still seems to be after heavily discounted technology companies, while executing succe...
Summary Shares of neuro-pharmaceutical concern Biohaven Ltd. (BHVN) have more than doubled after being spun out as part of Pfizer’s (PFE) purchase of the legacy company’s migraine assets. The one-month move was accomplished despite a secondary that diluted shareholders by ...
Biohaven press release ( NYSE: BHVN ): Q3 Non-GAAP EPS of -$1.25. Cash as of September 30, 2022 was $50.7 million, excluding $0.8 million of restricted cash, compared to $76.1 million as of December 31, 2021. For further details see: Biohaven Non-GAAP EPS of -$1....
Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments PR Newswire Biohaven Ltd. launched post-closing of the Biohaven Pharmaceutical Holding Company Ltd. sale to Pfizer on October 4, 2022 , and completed a public offeri...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...
2024-05-29 11:00:21 ET Leonid Timashev from RBC Capital issued a price target of $59.00 for BHVN on 2024-05-29 09:14:00. The adjusted price target was set to $59.00. At the time of the announcement, BHVN was trading at $28.69. The overall price target consensus is at $23...